$15.60 0.00%
AGEN Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Agenus

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer.


Agenus
Price $15.60
Target Price Sign up
Volume 481,500
Market Cap $328M
Year Range $4.97 - $18.56
Dividend Yield 0%
PE Ratio 1.35
Revenue per Employee $302,657
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2428M110,00028M-62M-30M-3.040
Q4 '2384M260,00083M-46M1M-0.130
Q3 '2324M300,00024M-62M-43M-0.160
Q2 '2325M250,00025M-69M-52M-0.200
Q1 '2323M2.3M21M-68M-52M-0.220

Insider Transactions View All

ARMEN GARO H filed to buy 625,969 shares at $0.6.
February 15 '24
WIINBERG ULF filed to buy 124,063 shares at $0.8.
November 17 '23
O'Day Steven J filed to sell 61,321 shares at $3.1.
January 6 '22

What is the Market Cap of Agenus?

The Market Cap of Agenus is $328M.

What is Agenus' PE Ratio?

As of today, Agenus' PE (Price to Earnings) ratio is 1.35.

How Many People Work at Agenus?

As of our latest update, Agenus employed approximately 533 people worldwide. However, it's important to note that Agenus' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Agenus' revenue per employee?

$302,657. To calculate Agenus' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Agenus?

Currently, the price of one share of Agenus stock is $15.60.

How can I analyze the AGEN stock price chart for investment decisions?

The AGEN stock price chart above provides a comprehensive visual representation of Agenus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Agenus shares. Our platform offers an up-to-date AGEN stock price chart, along with technical data analysis and alternative data insights.

Does AGEN offer dividends to its shareholders?

As of our latest update, Agenus (AGEN) does not offer dividends to its shareholders. Investors interested in Agenus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Agenus?

Some of the similar stocks of Agenus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.